Dean Investment Associates LLC Has $383,000 Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Dean Investment Associates LLC lowered its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 84.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,315 shares of the company's stock after selling 29,155 shares during the quarter. Dean Investment Associates LLC's holdings in Prestige Consumer Healthcare were worth $383,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in Prestige Consumer Healthcare during the third quarter worth $264,000. Jane Street Group LLC increased its stake in Prestige Consumer Healthcare by 28.3% in the 3rd quarter. Jane Street Group LLC now owns 65,373 shares of the company's stock valued at $4,713,000 after buying an additional 14,434 shares during the last quarter. Wellington Management Group LLP bought a new stake in Prestige Consumer Healthcare during the 3rd quarter worth about $6,342,000. WESCAP Management Group Inc. boosted its stake in shares of Prestige Consumer Healthcare by 5.3% during the 3rd quarter. WESCAP Management Group Inc. now owns 18,892 shares of the company's stock worth $1,362,000 after buying an additional 945 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Prestige Consumer Healthcare by 13.7% in the 3rd quarter. Stifel Financial Corp now owns 19,299 shares of the company's stock valued at $1,391,000 after acquiring an additional 2,322 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company's stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William P'pool sold 8,987 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a "hold" rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research note on Monday. Finally, DA Davidson reissued a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded down $1.05 during mid-day trading on Monday, reaching $83.28. The company's stock had a trading volume of 249,832 shares, compared to its average volume of 251,315. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 1-year low of $57.95 and a 1-year high of $86.36. The business has a 50-day simple moving average of $77.01 and a two-hundred day simple moving average of $72.05. The stock has a market cap of $4.11 billion, a P/E ratio of 20.26, a PEG ratio of 2.37 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter last year, the firm posted $1.07 EPS. The company's quarterly revenue was down .9% on a year-over-year basis. As a group, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.